Mood State Blood Biomarkers: A Discovery-Based Approach

情绪状态血液生物标志物：基于发现的方法

• 批准号: 8195976
• 负责人: Alexander B Niculescu
• 金额: --
• 依托单位: RLR VA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-10-01 至 2012-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8195976
• 关键词: Adverse effects; Affect; Alcoholism; Algorithms; Animal Model; Animals; Area; Autopsy; Biological; Biological Markers; Bipolar Depression; Bipolar Disorder; Blood; Blood Tests; Blood specimen; Brain; Candidate Disease Gene; Caring; Cell Culture Techniques; Clinical; Clinical Treatment; Clinical assessments; Complex; Control Groups; Data; Data Set; Detection; Development; Diagnosis; Diagnostic and Statistical Manual; Disease; Early treatment; Environmental Exposure; Etiology; Family member; Foundations; Future; Gene Expression; Gene Expression Profiling; Genes; Genetic; Genetic Heterogeneity; Genetic Polymorphism; Goals; Growth Factor; Harvest; Health; Health Care Costs; Healthcare; Hospitalization; Human; Human Genetics; Human Herpesvirus 4; Impaired cognition; Individual; Inflammatory; Interview; Investigation; Knowledge; Laboratories; Lead; Linkage Disequilibrium Mapping; Lymphocyte; Measurement; Measures; Mental disorders; Meta-Analysis; Methodology; Methods; Modality; Modeling; Mood Disorders; Moods; Morphologic artifacts; Nature; Neurobiology; Paper; Pathway interactions; Patient Self-Report; Patients; Peripheral; Personal Satisfaction; Pharmaceutical Preparations; Pharmacogenomics; Pilot Projects; Post-Traumatic Stress Disorders; Predictive Value; Predictive Value of Tests; Probability; Public Domains; Publishing; Quality of life; Relapse; Reliance; Research; Resources; Risk; Safety; Sampling; Schizophrenia; Sensitivity and Specificity; Series; Severities; Signal Transduction; Source; Specificity; Study Section; Symptoms; Testing; Time; Transgenic Organisms; Validation; Veterans; Visit; Whole Blood; Work; abstracting; base; cohort; data modeling; drug development; functional genomics; genetic association; genetic linkage; genetic linkage analysis; genetic manipulation; genome wide association study; human disease; human tissue; immune activation; impression; improved; information gathering; interest; lymphoblastoid cell line; male; myelination; neuropsychiatry; peripheral blood; positional cloning; prevent; public health relevance; response; success; trait; translational approach; true biomarker

DESCRIPTION (provided by applicant): Abstract: There are to date no clinical laboratory blood tests for mood disorders. Given the complex nature of mood disorders, the current reliance on patient self-report of symptoms and the clinician's impression on interview of patient is a rate limiting step in delivering the best possible care with existing treatment modalities, as well as in developing new and improved treatment approaches, including new medications. We propose, and provide proof of principle for, an approach to help identify state blood biomarkers for mood state. Such biomarkers can serve as a basis for objective clinical laboratory tests. Our approach is based on the integration of human and animal model data, as a way of reducing the false-positives inherent in each approach and helping identify true biomarker molecules. We propose to measure gene expression differences in fresh blood samples from subjects with DIGS- diagnosed bipolar disorders that have low mood scores vs. those that have high mood scores at the time of the blood draw. We will then integrate our human blood gene expression data with human postmortem data, human genetic linkage/association data and animal model gene expression data (using data from two different animal models studied in our group, one pharmacogenomic and one transgenic), an approach called Convergent Functional Genomics, as a Bayesian strategy for cross-validating and prioritizing findings. In pilot studies for this project, we have identified a series of high probability blood candidate biomarker genes for mood state that deserve future scrutiny. Topping our list of candidate biomarker genes for mood state we have five genes involved in myelination (Mbp, Edg2, Mag, Pmp22 and Ugt8), and six genes involved in growth factor signaling (Fgfr1, Fzd3, Erbb3, Igfbp4, Igfbp6, and Ptprm). All of these genes have prior evidence of differential expression in human postmortem brains from mood disorder subjects. A predictive score developed based on a panel of ten top candidate biomarkers (five for high mood, five for low mood) shows sensitivity and specificity for high mood and low mood states, in two independent cohorts. Our preliminary studies suggest that blood biomarkers may offer an unexpectedly informative window into brain functioning and disease state, specifically in regards to mood disorders. This exciting preliminary work needs to be carefully extended and replicated in a larger independent cohort, as well as compared to normal controls to derive additional normative data, which is what we propose to do in this project. PUBLIC HEALTH RELEVANCE: Potential Impact on Veterans Health Care: A more objective assessment of mood state with biomarker profiling will lead to more targeted treatments for veterans affected by psychiatric disorders involving mood dysregulation primarily, such as in bipolar disorder or depression, and secondarily, such as in PTSD, with improved efficacy and decreased side-effects. This will have an impact on patient health, well- being, safety, quality of life, and independent functioning, as well as decrease hospitalizations and overall health-care costs. Moreover, biomarker profiling may help with assessing response to treatment, risk of relapse, and early intervention efforts to prevent the full-blown development of illness in susceptible individuals.

描述（由申请人提供）： 摘要：迄今为止没有针对情绪障碍的临床实验室血液检查。鉴于情绪障碍的复杂性质，目前对患者症状的自我报告以及临床医生对患者访谈的印象是限制速率的限制步骤，即通过现有治疗方式以及开发新的和改进的治疗方法，包括新药物，包括新的治疗方法。我们提出并提供原理证明，以帮助确定情绪状态的状态血液生物标志物。这种生物标志物可以作为客观临床实验室测试的基础。 我们的方法基于人类和动物模型数据的整合，是一种减少每种方法固有的假阳性并有助于识别真正的生物标志物分子的方式。我们建议从具有低情绪评分的受试者的新鲜血液样本中测量新鲜血液样本中的基因表达差异，而在抽血时具有较高情绪得分的受试者。然后，我们将将人类血液基因表达数据与人类遗产数据，人类遗传链接/关联数据和动物模型基因表达数据（使用来自我们组中研究的两个不同动物模型的数据，一种药物基因组和一种转基因），一种称为收敛功能基因组学的方法，作为贝叶斯的交叉允许策略，用于交叉销售和优先确定发现。 在该项目的试点研究中，我们已经确定了一系列值得未来审查的情绪状态血液候选生物标志物基因。在我们的情绪状态候选生物标志物基因的列表中，我们有五个基因参与髓鞘（MBP，EDG2，MAG，PMP22和UGT8），以及涉及生长因子信号传导的六个基因（FGFR1，FZD3，ERBB3，IGFBP4，IGFBP4，IGFBP6，IGFBP6和PTPRM）。所有这些基因都有先前的证据表明，在人类后大脑中，情绪障碍受试者的表达差异。在两个独立的队列中，基于十个顶级候选生物标志物（高情绪的五个，高情绪）的小组成立了预测分数（高情绪低下，低情绪为5），对高情绪和低情绪状态的特异性表现出敏感性和特异性。我们的初步研究表明，血液生物标志物可能会为大脑功能和疾病状态提供意外的信息，特别是在情绪障碍方面。 这项令人兴奋的初步工作需要在更大的独立队列中仔细扩展和复制，并且与正常对照组相比，这是我们在该项目中提出的其他规范性数据的。 公共卫生相关性： 对退伍军人卫生保健的潜在影响：对情绪状态进行生物标志物分析的更客观评估将导致对受精神疾病影响的退伍军人的更具针对性的治疗，这些疾病主要是涉及情绪失调的精神疾病，主要是双相情感障碍或抑郁症，其次，例如，在PTSD中，具有改善的效率和副作用。这将影响患者健康，健康，安全，生活质量和独立功能，以及降低住院和整体医疗费用。此外，生物标志物分析可能有助于评估对治疗的反应，复发风险以及早期干预措施，以防止易感人群的疾病全面发展。